Group 1: Chemical Industry Performance - The chemical index experienced a comprehensive increase, with the chemical raw materials index rising by 3.31%, chemical machinery index by 1.06%, pharmaceutical index by 1.06%, and pesticide and fertilizer index by 2.54% [1] - In contrast, the oil sector saw a decline, with the oil processing index down by 0.91%, oil extraction index down by 3.26%, and oil trading index down by 6.96% [1] Group 2: Oil Price Trends - International crude oil prices significantly decreased, with WTI settling at $65.52 per barrel, down 12.56% from June 20, and Brent at $67.77 per barrel, down 12% [1] - The top five rising petrochemical products included butanone up by 101.77%, liquid chlorine up by 7.35%, and isooctyl acrylate up by 5.71% [1] - The top five declining petrochemical products included US light crude down by 12.56%, vitamin D3 down by 12.50%, and propane down by 9.17% [1] Group 3: Capital Market Performance of Chemical Companies - The top five gaining listed chemical companies in the Shanghai and Shenzhen markets included Dazhongnan up by 50%, Taihe Technology up by 48.09%, and Tiancheng New Materials up by 31.41% [2] - The top five declining listed chemical companies included Tongyuan Petroleum down by 19.75%, Jinniu Chemical down by 14.44%, and Beiken Energy down by 17.74% [2]

Market Trends - The domestic market indices showed positive performance with the Shanghai Composite Index closing at 3,444.43, up by 0.59%, indicating an expected improvement in supply and demand conditions [4] Agricultural Industry - The agricultural sector saw a weekly increase in the Shanghai and Shenzhen 300 Index by 1.95%, with the agriculture, forestry, animal husbandry, and fishery sector rising by 0.80% [9] - Pig prices increased week-on-week, with average prices in key provinces such as Sichuan, Guangdong, and Henan at 13.90, 15.94, and 14.88 CNY/kg respectively, reflecting increases of 1.46%, 2.57%, and 3.48% [9] - The report highlights the potential for Hai Da Group as an investment opportunity due to expected recovery in the feed industry driven by lower raw material prices and improving breeding conditions [7][9] Chemical Pharmaceutical Industry - BGB-43395, a CDK4 inhibitor developed by BeiGene, shows promising initial efficacy and safety in treating previously treated breast cancer and solid tumor patients [10] - The drug exhibits high selectivity for CDK4 and is expected to enter Phase III trials for HR+/HER2- metastatic breast cancer, with the second-line study anticipated to start in Q4 2025 [10][11] - The global market for CDK4/6 inhibitors is projected to reach approximately $13 billion by 2024, indicating significant growth potential for BGB-43395 [10] Textile and Apparel Industry - Bosideng reported a revenue of 25.902 billion CNY for FY2024/25, a year-on-year increase of 11.6%, with a net profit of 3.514 billion CNY, up 14.3% [11][15] - The brand's down jacket business showed steady growth, with revenue from this segment reaching 21.668 billion CNY, a 11.0% increase year-on-year [11] - The company opened 253 new stores, enhancing its operational capabilities and channel management [12][15] Photovoltaic Glass Industry - Major photovoltaic glass manufacturers plan to collectively reduce production by 30% starting in July, which is expected to improve the supply-demand balance in the market [14][16] - The report recommends leading photovoltaic glass companies such as Fuyao Glass and Xinyi Solar as potential investment opportunities due to anticipated improvements in market conditions [14]

第二条 公司董事会是公司内幕信息的管理机构，应当保证公司所登记的内幕信息 知情人档案信息的真实、准确、完整。董事长为主要责任人，董事会秘书负责组织实施， 办理公司内幕信息知情人的登记入档和报送事宜。董事长与董事会秘书应当对内幕信息 知情人档案的真实、准确和完整签署书面确认意见。 第三条 董事会办公室为公司内幕信息登记备案工作的日常工作部门，是公司唯一 的信息披露机构，统一负责证券监管机构、证券交易所、机构及个人投资者、新闻媒体 的接待、咨询（质询）、服务工作。 第四条 公司其他部门、个人以及本制度规定的内幕信息知情人（单位/个人）未经 董事会授权不得向外界泄露、报道、传送有关涉及公司重大信息及信息披露的内容。公 司各部门、子（分）公司等负责人为其管理范围内的保密工作责任人，负责其涉及的内 幕信息的报告、传递。 华东医药股份有限公司 第一章 总则 第一条 为加强华东医药股份有限公司（以下简称"公司"或"本公司"）内幕信息管理， 做好公司内幕信息保密工作，防控内幕交易风险，维护公司信息披露的公平原则，保护 公司股东的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》（以 下简称"《证券法》"）《上市公 ...

第二章 董事会组成和职权 华东医药股份有限公司 第一章 总则 第二条 公司设立董事会。 第三条 董事会由 11 名董事组成，其中职工代表董事 1 名，独立董事 4 名，独立董事 中至少包括 1 名会计专业人士。董事会设董事长 1 人，董事长由董事会以全体董事的过半 数选举产生。 第四条 董事会行使下列职权： 第一条 为规范华东医药股份有限公司（以下简称"公司"或"本公司"）董事会议事和 决策程序，进一步建立和健全公司治理结构，提高董事会的工作效率、工作质量、规范运 作及科学决策水平，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司治理准则》《深圳证券交易 所上市公司自律监管指引第 1 号——主板上市公司规范运作》《深圳证券交易所股票上市 规则》等法律、法规及《华东医药股份有限公司章程》的有关规定，制定本议事规则。 （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订公司的利润分配方案和弥补亏损方案； （五）制订公司增加或者减少注册资本、发行债券或其他证券及上市方案； （六）拟订 ...

华东医药股份有限公司 第一章 总则 第一条 为规范华东医药股份有限公司（以下简称"本公司"或"公司"）的信息披露行 为，保证信息披露的真实、准确、完整、及时、公平，保护公司、股东、债权人及其他 利益相关者的合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》 （以下简称"《证券法》"）《上市公司信息披露管理办法》《深圳证券交易所上市公司 自律监管指引第 1 号——主板上市公司规范运作》《深圳证券交易所上市公司自律监管 指引第 5 号——信息披露事务管理》《深圳证券交易所股票上市规则》（以下简称"《上 市规则》"）等有关法律、法规及《华东医药股份有限公司章程》（以下简称"公司章 程"）的规定，制定本制度。 第二条 本制度所称"信息"是指根据相关法律、法规、部门规章及证券监管部门的规 范性文件，将可能对公司股票及衍生品种价格产生较大影响而投资者尚未得知的重大信 息及证券监督管理部门要求披露的信息。本制度所称"披露"是指在规定的时间内在中国 证券监督管理委员会（以下简称"中国证监会"）指定的媒体上、按照规定的方式向社 会公众公布前述信息，并按规定报送证券监督管理部门。 第三条 信息披露义务人包括： 关人员 ...

华东医药股份有限公司 第一章 总则 第一条 为规范华东医药股份有限公司（以下简称"公司"或"本公司"）的公司行 为，明确董事会秘书的职责权限，根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称《证券法》）、《深圳证券交易所股 票上市规则》（以下简称《上市规则》）、《华东医药股份有限公司章程》（以下简称 "公司章程"）及其他有关规定，制定本工作细则。 第二条 董事会秘书为公司的高级管理人员，对董事会负责。法律、行政法规、部门 规章、《上市规则》及公司章程等对公司高级管理人员的有关规定，适用于董事会秘书。 第二章 任职资格 第三条 董事会秘书应当具备履行职责所必需的财务、管理、法律专业知识，具有良 好的职业道德和个人品德，并取得证券交易所颁发的董事会秘书资格证书。 第四条 有下列情形之一的人士不得担任公司董事会秘书: （一）《上市规则》第 4.3.3 条规定的不得担任上市公司董事、高级管理人员的情形； （二）最近三十六个月受到中国证券监督管理委员会（以下简称"中国证监会"） 行政处罚； （三）最近三十六个月受到证券交易所公开谴责或者三次以上通报批评； （四）中国证监会、深 ...

华东医药股份有限公司 第一章 总则 第一条 为进一步完善华东医药股份有限公司（以下简称"公司"或"本公司"） 法人治理结构，明确总经理的职责，保障总经理高效、协调、规范地行使职权，根据 《中华人民共和国公司法》《上市公司治理准则》等法律法规和《华东医药股份有限公 司章程》（以下简称"公司章程"）的规定，并结合公司的实际情况，特制定本细则。 第二条 总经理是董事会领导下的公司行政负责人，应当遵守法律、行政法规和公 司章程的规定，履行诚信和勤勉的义务，负责贯彻落实董事会决议，主持公司的生产经 营和日常管理工作，并对董事会负责。 第二章 总经理的任职资格与任免程序 第三条 总经理任职应当具备下列条件： （一）具有较丰富的经济理论知识、管理知识及实践经验，具有较强的经营管理能 力； （二）具有调动员工积极性、建立合理的组织机构、协调各种内外关系和统揽全局 的能力； （三）具有一定年限的企业管理或经济工作经历，精通本行，熟悉多种行业的生产 经营业务和掌握国家有关政策、法律、法规； （四）诚信勤勉、廉洁奉公、民主公道； （五）年富力强，有较强的使命感和积极开拓的进取精神。 第四条 有下列情形之一的，不得担任本公司总经理： ...

Core Points - The document outlines the procedures and requirements for East China Pharmaceutical Co., Ltd. to select and appoint accounting firms, ensuring compliance with relevant laws and regulations [1][2][12] - The selection process involves the audit committee, which is responsible for proposing, evaluating, and recommending accounting firms to the board of directors and shareholders [6][7][11] Group 1: General Provisions - The company must adhere to laws such as the Company Law and Securities Law when appointing accounting firms [1] - The selection of accounting firms must be approved by the audit committee, board of directors, and shareholders [1][2] Group 2: Quality Requirements for Accounting Firms - Selected accounting firms must possess independent qualifications and meet specific regulatory requirements [2] - Firms must have a good reputation and a record of quality management, with no significant penalties in the last three years related to securities and futures business [2][5] Group 3: Selection Procedures - The audit committee can initiate the selection process and is responsible for drafting policies and evaluating proposals [6][7] - Various selection methods include competitive negotiation, public bidding, and invitation bidding [3][4] Group 4: Evaluation Criteria - Evaluation factors for accounting firms include audit fees, qualifications, quality management, and risk management capabilities [5][6] - Quality management must account for at least 40% of the evaluation score, while audit fees should not exceed 15% [5] Group 5: Supervision and Reporting - The company must disclose information about the accounting firms, including service duration and audit fees, in annual reports [11] - The audit committee is tasked with monitoring compliance with laws and evaluating the performance of the appointed accounting firms [11][30]

上海君澜律师事务所 关于 浙江东亚药业股份有限公司 回购注销部分限制性股票 之 法律意见书 二〇二五年六月 上海君澜律师事务所 法律意见书 上海君澜律师事务所 关于浙江东亚药业股份有限公司 回购注销部分限制性股票之 法律意见书 致：浙江东亚药业股份有限公司 上海君澜律师事务所（以下简称"本所"）接受浙江东亚药业股份有限公司（以 下简称"公司"或"东亚药业"）的委托，根据《上市公司股权激励管理办法》（以 下简称"《管理办法》"）、《浙江东亚药业股份有限公司 2024 年限制性股票激励计 划》（以下简称"《激励计划》"或"本次激励计划"）的规定，就东亚药业回购注 销本次激励计划 1 名激励对象已获授但尚未解除限售的限制性股票（以下简称"本次 回购注销"）相关事项出具本法律意见书。 对本法律意见书，本所律师声明如下： （一）本所律师依据《中华人民共和国证券法》《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定及本法律意见书 出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实 信用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整， ...

Core Viewpoint - The company announced the repurchase and cancellation of 14,000 restricted stocks due to one incentive object resigning, with a repurchase price of 9.47 yuan per share [1][6][10]. Summary by Sections Announcement Details - The company’s board approved the repurchase of restricted stocks at a meeting held on June 30, 2025, following the resignation of one incentive object [1][2]. - The total number of restricted stocks to be repurchased is 14,000 shares, which represents 0.01% of the total share capital of 114,739,776 shares as of June 29, 2025 [6][7]. Repurchase Price and Funding - The repurchase price for the restricted stocks is set at 9.47 yuan per share, totaling 132,580 yuan, which will be funded entirely from the company’s own funds [6][7]. Impact on Share Capital Structure - After the repurchase and cancellation, the company’s total share capital will decrease from 114,739,776 shares to 114,725,776 shares [7][9]. - The number of restricted shares will decrease from 2,156,103 to 2,142,103 shares, while the number of unrestricted shares remains unchanged at 112,583,673 [8]. Compliance and Approval - The repurchase has been authorized by the company’s third extraordinary general meeting in 2024, and no further shareholder approval is required [6][9]. - The supervisory board has confirmed that the repurchase complies with relevant regulations and will not adversely affect the company’s financial status or operational results [9][10].